Shionogi was founded in 1878 in Osaka, Japan where our headquarters remain. The company has grown to become a major research-driven pharmaceutical company dedicated to placing the highest value on patient care. Shionogi has a strong heritage in the discovery and development of globally important therapies.
Shionogi & Co., Ltd has recently launched its new European Headquarters, Shionogi Limited in London. Establishing the new headquarters is an important milestone for the Company as it further expands the organization into the global arena.
Shionogi develops and commercializes pharmaceutical products. We have been providing innovative medicines essential to people's health for over 130 years. Shionogi Inc.'s portfolio includes products for pain, pediatric conditions, cardiovascular disease, diabetes, and women's health.
Shionogi's Policy is to "supply the best possible medicine to protect the health and wellbeing of the patients we serve." Our mission, based on this Policy, as a research-driven pharmaceutical company, is to deliver pharmaceuticals that offer the greatest possible level of satisfaction to patients, their families, and healthcare providers and that improve quality of life (QOL) for patients and their families worldwide. To achieve the above goal, we are constantly engaged in research, development, manufacturing, and marketing activities, with a primary focus on prescription drugs, OTC drugs and diagnostics.
Research & Development
As a research-driven pharmaceutical company, Shionogi carries out its activities aggressively and rapidly, making concerted efforts.
According to the Shionogi Product Policy, Shionogi's products are manufactured with a strong emphasis on safety and eco-friendliness, not to mention product quality.
Shionogi is devoted to providing information, based on scientific evidence, on the proper use of our medical products, including prescription drugs, OTC drugs, diagnostic reagents and devices.